EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cucurbitacin IIb attenuates cancer cachexia induced skeletal muscle atrophy by regulating the IL ‐6/ STAT3 / FoxO signaling pathway

Yaxian Wang, Xipeng Sun, Quanjun Yang, Cheng Guo iD

Phytotherapy Research · 2023-08 · 37 (8) · 3380-3393

DOI: 10.1002/ptr.7811 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytotherapy Research, online erschienen am 19.04.2023. Verfasst von Yaxian Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Cachexia, Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The main features of cancer cachexia include skeletal muscle atrophy, which can significantly reduce the quality of life of patients. Clinical treatment of cancer cachexia is mainly based on nutritional therapy and physical exercise; medication only improves appetite but does not reverse the symptoms of skeletal muscle wasting. In this work, we systematically studied the underlying molecular mechanisms by which cucurbitacin IIb (CuIIb) ameliorates muscle wasting in cancer cachexia both in vitro and in vivo. CuIIb significantly ameliorated the chief features of cancer cachexia in vivo, alleviating weight loss, food intake, muscle wasting, adipose tissue depletion, and organ weight reductions. In vitro, CuIIb (10 and 20 μM) dose‐dependently attenuated conditioned medium (CM)‐induced C2C12 myotube atrophy. Collectively, our findings demonstrated that CuIIb prevented the upregulation of the E3 ubiquitin ligase muscle atrophy Fbox protein (MAFbx), myosin heavy chain (MyHC), and myogenin (MyoG) and impacted protein synthesis and degradation. In addition, CuIIb decreased the phosphorylation of Tyr705 in STAT3 by regulating the IL‐6/STAT3/FoxO pathway to reduce skeletal muscle atrophy in cancer cachexia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CachexiaNeoplasmsHumansInterleukin-6Quality of LifeMuscular AtrophySignal TransductionMuscle, SkeletalMuscle Fibers, SkeletalSTAT3 Transcription FactorCucurbitacins

Stichwörter der Autor:innen

IL-6/STAT3/FoxO pathwaySTAT3cancer cachexiacucurbitacin IIbskeleta muscle atrophy

Substanzen

Interleukin-6STAT3 Transcription Factorcucurbitacin IIbCucurbitacinsSTAT3 protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

ORCID-Profile: Cheng Guo

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, Y., Sun, X., Yang, Q., & Guo, C. (2023). Cucurbitacin IIb attenuates cancer cachexia induced skeletal muscle atrophy by regulating the IL ‐6/ STAT3 / FoxO signaling pathway. Phytotherapy Research, 37(8), 3380-3393. https://doi.org/10.1002/ptr.7811

Vancouver

Wang Y, Sun X, Yang Q, Guo C. Cucurbitacin IIb attenuates cancer cachexia induced skeletal muscle atrophy by regulating the IL ‐6/ STAT3 / FoxO signaling pathway. Phytotherapy Research. 2023;37(8):3380-3393. doi:10.1002/ptr.7811

BibTeX
@article{Wang2023,
  author = {Wang, Yaxian and Sun, Xipeng and Yang, Quanjun and Guo, Cheng},
  title = {Cucurbitacin IIb attenuates cancer cachexia induced skeletal muscle atrophy by regulating the IL ‐6/ STAT3 / FoxO signaling pathway},
  journal = {Phytotherapy Research},
  year = {2023},
  volume = {37},
  number = {8},
  pages = {3380--3393},
  doi = {10.1002/ptr.7811}
}
Kostenlos starten →